Letters to the Editor
Vol. 15 No. 1 (2023): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
https://doi.org/10.4084/MJHID.2023.014

Neutropenıa Secondary to Sars-Cov2 Vaccınatıon in Post-Hematopoıetıc Stem Cell Transplant (Hsct) Patıents

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: February 28, 2023
1212
Views
836
Downloads
329
HTML
bone marrow transplantation, Neutropenia, anti SARS-CoV-2 vaccine

Authors

LUIS MIGUEL JUAREZ-SALCEDO
DR.LUISJUAREZ@GMAIL.COM
La Princesa University Hospital, Spain.
Samantha Feijóo
Malignant Hematology Department. La Princesa University Hospital. Madrid, Spain., Spain.
Cristina García
Alejandro Alonso
Beatriz Aguado
Javier Ortiz
Angela Figuera
Rafael de la Cámara

SARS-Cov2 s, caused a high mortality in patients with some degree of immunosuppression, like those that receive a hematopoietic progenitor transplant. Since December 2020, several vaccines have been developed having been key in decreasing complications and mortality in this group of patients. Different articles have described the presence of thrombopenia related to the administration of vaccines, however, there are few data on the occurrence of neutropenia as a side effect after administration. We present several cases of neutropenia (defined as absolute neutrophil count (ANC) less than 2,000/mm3), after vaccination in hematopoietic progenitor transplant (HPT) recipients performed in our center during 2021.

 

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2021;17(3):519–527.
Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021;384(11):10.
Baden LR, El Sahly HM, Essink B. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
Lee EJ, Cines DB, Gernsheimer T. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96(5):534–537.
Perricone C, Ceccarelli F, Nesher G. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases. Immunol Res. 2014;60(2-3):226–235.
Ali H, Ngo D, Aribi A, Arslan S, Dadwal S, Marcucci G, Nakamura R, Forman SJ, Chen J, Al Malki MM. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. Transplant Cell Ther. 2021 Nov;27(11):938.e1-938.e6.
Ram R, Hagin D, Kikozashvilli N, Freund T, Amit O, Bar-On Y, Beyar-Katz O, et al. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study. Transplant Cell Ther. 2021 Sep;27(9):788-794.

Ethics Approval

Hematology findings in COVID 19 patient

How to Cite



“Neutropenıa Secondary to Sars-Cov2 Vaccınatıon in Post-Hematopoıetıc Stem Cell Transplant (Hsct) Patıents” (2023) Mediterranean Journal of Hematology and Infectious Diseases, 15(1), p. e2023014. doi:10.4084/MJHID.2023.014.
Copyright (c) 2023 LUIS MIGUEL JUAREZ-SALCEDO, Samantha Feijóo, Cristina García, Alejandro Alonso, Beatriz Aguado, Javier Ortiz, Angela Figuera, Rafael de la Cámara Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.